Status: Recruiting
Chiauranib Plus Weekly Paclitaxel in Patients with Platinum-refractory or Platinum-resistant Recurrent Ovarian Cancer
This randomized, double-blind, 2-arm study will evaluate the efficacy and safety of Chiauranib plus weekly paclitaxel versus placebo plus weekly paclitaxel in patients with Platinum-refractory or Platinum-resistant Recurrent ovarian cancer.
Participants needed: 454
Trial details
Phase: Phase 3Age: 18-70Biological sex: FemaleType: InterventionalSponsor: Chipscreen Biosciences, Ltd.Updated: Oct 18, 2024Locations: 1
Eligibility criteria
Willingness to sign a written informed consent document . [+12]
Patients received vascular endothelial growth factor(VEGF)/vascular endothelial... [+29]